ORANGE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) announced today that 98% of its Alignment Health Plan members are enrolled in plans rated 4 stars or greater by the Centers for Medicare & Medicaid Services (CMS) for 2025. Every year, CMS evaluates Medicare Advantage plans based on a 5-star rating – with 5 stars representing “excellent” performance – to help Medicare beneficiaries compare health plans based on quality and performance.
“Achieving these high star ratings under increasingly stringent CMS criteria demonstrates our leadership in the Medicare Advantage space,” said John Kao, founder and CEO, Alignment Healthcare. “Our excellent performance reflects our deep commitment to the seniors we serve, ensuring they get the quality, respect and care they deserve. We’re not just following best practices; we’re setting the benchmark for what Medicare Advantage should be.”
“Our success in attaining such strong star ratings year after year is a direct result of our unwavering focus on our members’ health and wellness needs,” said Dawn Maroney, president, markets of Alignment Healthcare, and CEO of Alignment Health Plan. “Our ability to consistently deliver high-quality care shows that we’re doing Medicare Advantage right, empowering seniors to live healthier and fuller lives.”
Key Highlights of Alignment Health Plan’s 2025 Star Ratings:
CMS’s 5-star ratings system is based on factors that include feedback from members, the number of members who left or stayed with a plan, the number of complaints about a plan, and other clinical quality metrics.
CMS Star Ratings are posted at Medicare.gov. Medicare’s annual enrollment period runs from Oct. 15 to Dec. 7 for plan benefits starting Jan. 1, 2025. For more information about Alignment’s plans and services, visit www.alignmenthealthplan.com or call 1-888-979-2247, TTY 711, seven days a week, 8 a.m. to 8 p.m. A licensed agent may answer the call.
NOTE: Information in this release is based on 2025 Star Ratings data published by CMS on Oct. 10, 2024 and plan enrollment as of September 2024.
About Alignment Health
Alignment Health is championing a new path in senior care that empowers members to age well and live their most vibrant lives. A consumer brand name of Alignment Healthcare (NASDAQ: ALHC), Alignment Health’s mission-focused team makes high-quality, low-cost care a reality for its Medicare Advantage members every day. Based in California, the company partners with nationally recognized and trusted local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology, AVA®. As it expands its offerings and grows its national footprint, Alignment upholds its core values of leading with a serving heart and putting the senior first. For more information, visit www.alignmenthealth.com.
Investor Contact
Harrison Zhuo
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Priya Shah
mPR, Inc. for Alignment Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
___________________________________
1 Centers for Medicare & Medicaid Services Medicare Advantage/Part D Contract and Enrollment Data, September 2024 MA State/County Penetration, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MCRAdvPartDEnrolData/MA-State-County-Penetration
Last Trade: | US$18.24 |
Daily Change: | -1.24 -6.37 |
Daily Volume: | 5,891,140 |
Market Cap: | US$3.500B |
April 15, 2025 February 28, 2025 February 27, 2025 January 13, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load